Physiological changes in the juvenile euryhaline teleost, the tilapia Oreochromis hornorum, injected with E. coli-derived homologous growth hormone.
Growth is a complex process in fish. This study was designed to test the effect of different levels of recombinant tilapia growth hormone (tiGH) injected intraperitoneally in juvenile hybrid tilapia Oreochromis hornorum. Tilapia GH cDNA was cloned from hybrid O. hornorum tilapia. The mature protein was expressed in E. coli under regulation of the phage T7 promoter. The E. coli-derived tiGH was partially purified to 67% purity and, following renaturation, was shown to be biologically active in in vivo and in vitro assays. Recombinant tiGH stimulated extracellular matrix synthesis as shown by 35S-sulfate uptake in ceratobranchial cartilage explants. Zero, 0.1, 0.5 and 2.5 µg tiGH/g body weight (gbw) were injected in tilapia, and the effects on the growth-promoting action, hepatosomatic index (HSI), and mRNA insulin-like growth factor (IGF) induction were measured. A significant increase in the body weight (P < 0.05) and length (P < 0.01) was observed in tilapia receiving 0.5 µg tiGH/gbw. However, tilapia receiving 0.1 and 2.5 µg tiGH/gbw did not show an increase in body weight and length with respect to the control group receiving BSA injections. Binding sites for the recombinant tiGH were identified in the liver. Consistent with its somatotropic actions, the IGF mRNA induction was observed in the groups injected with 0.1 and 0.5 µg tiGH/gbw (P < 0.05). No significant increase in the HSI was detected in the injected groups when compared to the control group. These results demonstrated that the injection of biologically active E. coli-derived tiGH produces physiological changes in juvenile tilapia that ultimately resulted in a growth-promoting action only at a dose of 0.5 µg tiGH/gbw.